EE200000659A - 4-(3,5-bis-trifluorometüülbensüülamino)-2-etüül-6-trifluorometüül-3,4-dihüdro-2H-kin oliin-1-karboksüülhappe etüülestrid või nende soolad ja valmistamise meetodid - Google Patents

4-(3,5-bis-trifluorometüülbensüülamino)-2-etüül-6-trifluorometüül-3,4-dihüdro-2H-kin oliin-1-karboksüülhappe etüülestrid või nende soolad ja valmistamise meetodid

Info

Publication number
EE200000659A
EE200000659A EEP200000659A EEP200000659A EE200000659A EE 200000659 A EE200000659 A EE 200000659A EE P200000659 A EEP200000659 A EE P200000659A EE P200000659 A EEP200000659 A EE P200000659A EE 200000659 A EE200000659 A EE 200000659A
Authority
EE
Estonia
Prior art keywords
trifluoromethyl
ethyl
benzylamino
quinoline
dihydro
Prior art date
Application number
EEP200000659A
Other languages
English (en)
Estonian (et)
Inventor
Burns Damon David
Wayne Dugger Robert
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200000659A publication Critical patent/EE200000659A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000659A 1999-11-30 2000-11-30 4-(3,5-bis-trifluorometüülbensüülamino)-2-etüül-6-trifluorometüül-3,4-dihüdro-2H-kin oliin-1-karboksüülhappe etüülestrid või nende soolad ja valmistamise meetodid EE200000659A (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
EE200000659A true EE200000659A (et) 2001-08-15

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000659A EE200000659A (et) 1999-11-30 2000-11-30 4-(3,5-bis-trifluorometüülbensüülamino)-2-etüül-6-trifluorometüül-3,4-dihüdro-2H-kin oliin-1-karboksüülhappe etüülestrid või nende soolad ja valmistamise meetodid

Country Status (44)

Country Link
US (1) US6313142B1 (OSRAM)
EP (1) EP1125929B1 (OSRAM)
JP (1) JP3579345B2 (OSRAM)
KR (1) KR100408177B1 (OSRAM)
CN (1) CN1173953C (OSRAM)
AP (1) AP2000002011A0 (OSRAM)
AR (1) AR029775A1 (OSRAM)
AT (1) ATE315028T1 (OSRAM)
AU (1) AU784694B2 (OSRAM)
BG (1) BG105009A (OSRAM)
BR (1) BR0005636A (OSRAM)
CA (1) CA2327029C (OSRAM)
CO (1) CO5261552A1 (OSRAM)
CY (1) CY1104989T1 (OSRAM)
CZ (1) CZ20004407A3 (OSRAM)
DE (1) DE60025317T2 (OSRAM)
DK (1) DK1125929T3 (OSRAM)
DZ (1) DZ3079A1 (OSRAM)
EA (1) EA003668B1 (OSRAM)
EE (1) EE200000659A (OSRAM)
ES (1) ES2254109T3 (OSRAM)
GE (1) GEP20022798B (OSRAM)
GT (1) GT200000190A (OSRAM)
HN (1) HN2000000203A (OSRAM)
HR (1) HRP20000804A2 (OSRAM)
HU (1) HUP0004747A3 (OSRAM)
ID (1) ID28489A (OSRAM)
IL (1) IL139849A (OSRAM)
IS (1) IS5715A (OSRAM)
MA (1) MA25223A1 (OSRAM)
NO (1) NO20006039L (OSRAM)
NZ (1) NZ508509A (OSRAM)
OA (1) OA11494A (OSRAM)
PA (1) PA8503801A1 (OSRAM)
PE (1) PE20010913A1 (OSRAM)
PL (1) PL344208A1 (OSRAM)
SG (1) SG102603A1 (OSRAM)
SK (1) SK17792000A3 (OSRAM)
TN (1) TNSN00230A1 (OSRAM)
TW (1) TW591016B (OSRAM)
UA (1) UA65615C2 (OSRAM)
UY (1) UY26451A1 (OSRAM)
YU (1) YU71500A (OSRAM)
ZA (1) ZA200006947B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CA2470931A1 (en) * 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
CA2480439C (en) * 2002-04-11 2012-08-21 Roar Holding Llc Ex vivo method for determination of cetp activity and efficacy of heart disease treatment
KR20050055747A (ko) * 2002-10-04 2005-06-13 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료용의 ｐｇｄ2 수용체 길항제
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) * 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
AU2003303239A1 (en) * 2002-12-19 2004-07-14 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
WO2004078730A2 (en) * 2003-03-04 2004-09-16 Takasago International Corporation Method for producing optically active amines
EP1603554A1 (en) * 2003-03-17 2005-12-14 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
SI1603553T1 (sl) * 2003-03-17 2012-03-30 Japan Tobacco Inc Farmacevtski sestavki CETP inhibitorjev
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CA2537942A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
US20080269284A1 (en) * 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
RU2007135224A (ru) * 2005-02-24 2009-03-27 Милленниум Фармасьютикалз, Инк. (Us) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
KR20250049276A (ko) 2022-07-05 2025-04-11 뉴암스테르담 파마 비.브이. 오비세트라피브(obicetrapib)의 염 및 그의 제조 방법 및 그의 중간체

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (OSRAM) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
UA65615C2 (uk) 2004-04-15
DK1125929T3 (da) 2006-04-03
AP2000002011A0 (en) 2000-12-31
KR100408177B1 (ko) 2003-12-01
IS5715A (is) 2001-05-31
HN2000000203A (es) 2001-06-13
DZ3079A1 (fr) 2004-10-24
UY26451A1 (es) 2001-06-29
GEP20022798B (en) 2002-09-25
EA003668B1 (ru) 2003-08-28
YU71500A (sh) 2003-02-28
DE60025317T2 (de) 2006-08-03
AR029775A1 (es) 2003-07-16
AU784694B2 (en) 2006-06-01
EP1125929A1 (en) 2001-08-22
NO20006039L (no) 2001-05-31
US6313142B1 (en) 2001-11-06
ID28489A (id) 2001-05-31
HU0004747D0 (OSRAM) 2001-02-28
JP2001163859A (ja) 2001-06-19
DE60025317D1 (de) 2006-03-30
JP3579345B2 (ja) 2004-10-20
OA11494A (en) 2004-05-07
GT200000190A (es) 2002-04-27
SG102603A1 (en) 2004-03-26
CN1173953C (zh) 2004-11-03
ZA200006947B (en) 2002-05-27
CA2327029C (en) 2005-08-09
BR0005636A (pt) 2001-07-17
PL344208A1 (en) 2001-06-04
PE20010913A1 (es) 2001-09-10
ES2254109T3 (es) 2006-06-16
CZ20004407A3 (cs) 2002-06-12
NZ508509A (en) 2001-06-29
NO20006039D0 (no) 2000-11-29
BG105009A (en) 2001-11-30
HRP20000804A2 (en) 2001-06-30
CY1104989T1 (el) 2010-03-03
EA200001129A2 (ru) 2001-06-25
ATE315028T1 (de) 2006-02-15
TW591016B (en) 2004-06-11
CO5261552A1 (es) 2003-03-31
IL139849A (en) 2006-10-31
IL139849A0 (en) 2002-02-10
SK17792000A3 (sk) 2002-10-08
CN1302800A (zh) 2001-07-11
PA8503801A1 (es) 2002-07-30
HUP0004747A2 (hu) 2001-10-28
EA200001129A3 (ru) 2001-10-22
HUP0004747A3 (en) 2002-12-28
CA2327029A1 (en) 2001-05-30
AU7178900A (en) 2001-05-31
MA25223A1 (fr) 2001-07-02
KR20010052012A (ko) 2001-06-25
TNSN00230A1 (fr) 2005-11-10
EP1125929B1 (en) 2006-01-04
HK1038007A1 (en) 2002-03-01

Similar Documents

Publication Publication Date Title
EE200000659A (et) 4-(3,5-bis-trifluorometüülbensüülamino)-2-etüül-6-trifluorometüül-3,4-dihüdro-2H-kin oliin-1-karboksüülhappe etüülestrid või nende soolad ja valmistamise meetodid
EE05215B1 (et) Meetod tskloproplkarbokslhappe estrite ja derivaatide valmistamiseks
FI941082A0 (fi) Kinolonikarboksyylihappojohdannaiset, niiden valmistus ja käyttö
EE200200628A (et) Dihüdroksüestrite ja nende derivaatide valmistamismeetod
EE200200277A (et) 4-karboksüamino-2-etüül-1,2,3,4-tetrahüdrokinoliini kristall kui CETP inhibiitor
NO953367L (no) Anvendelse av substituerte 4-fenyl-6-amino-nikotinsyre-derivater som legemidler
FI951388A0 (fi) Substituoidut heterosykliset karboksyylihappoamidiesterit, niiden valmistus ja niiden käyttö lääkeaineina
NO20021368L (no) Fremgangsmåte for fremstilling av fenyleddiksyre derivater
HUP9900344A3 (en) Process for the preparation of an optically active indoline-2-carboxylic acid or derivative thereof
DE60001599D1 (de) Verfahren zur Herstellung von cis-1-2-[4-(6-Methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl-pyrrolidin
AU2002233353A1 (en) Process for the preparation of d-pantothenic acid and/or salts thereof
DE60036758D1 (de) Verfahren zur Herstellung von optisch aktiver 3,3,3-Trifluor-2-hydroxy-2-methylpropionsäure und deren Salze
DE60125915D1 (de) Verfahren zur herstellung von quinolin-derivaten und ihre zwischenstufen
DE60029847D1 (de) Verfahren zur Herstellung von erythro 3-Amino-2-hydroxybuttersäurederivaten
FI20040352L (fi) Menetelmä 4-(3-syaanifenyyli)-trifluorimetyyli-5-okso-1,4,5,6,7,8-heksahydrokinoliini-3-karboksyylihapon valmistamiseksi
ITMI992048A0 (it) Procedimento stereoselettivo per la preparazione di endo-3-amminoazabi cicloalcani
NO953322L (no) Anvendelse av 1,4-dihydropyridin-3,5-dikarboksylsyreestere som legemidler
DE60010725D1 (de) Herstellung von arylcarbonsäureestern
NO20015042D0 (no) Fremgangsmåter for fremstilling av optisk aktive aminosyrederivater
AU1101301A (en) 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
EE9400240A (et) 1-( 2-fluorotsüklopropüül ) -kinoloon- ja -naftüridoonkarboksüülhappe derivaadid ja nende soolad, nende saamismeetodid ja kasutamine
DE50012694D1 (de) Verwendung von fettsäurealkanolaminestern
RU2002102491A (ru) Производные хинолинкарбоновой кислоты или их соли
NO20014449D0 (no) Fremgangsmåte for fremstilling av 5-amino-8- alkylkinolonkarboksylsyrederivater og mellomprodukter ifremstillingen derav
NO994261L (no) Fremgangsmåte for fremstilling av trovafloxacinsyresalter